ORPH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Dzisiejszy wolumen	941 412
Średni wolumen	1.38M
Kapitalizacja rynkowa	0.00
EPS	$0 ( 2022-04-05 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.227
ATR14	$0.157 (18.05%)

Insider Trading

Date	Person	Action	Amount	type
2005-04-18	Orbimed Advisors Llc	Buy	0	Not reporting securities information.
2004-06-30	Stahl Pamela J	Buy	17 500	Stock Option (Right to Buy)
2004-06-15	Champsi Farah	Buy	5 000	Non-employee Director Stock Options (Right to Buy)
2004-06-15	Vida Julius A	Buy	5 000	Non-employee Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 3 transactions
Buy: 27 500 \| Sell: 0

Wolumen Korelacja

Długi: -0.13 (neutral)

Krótki: 0.26 (neutral)

Signal:(38.295) Neutral

Orphazyme A/S Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orphazyme A/S Korelacja - Waluta/Towar

0.20
( neutral )

-0.67
( moderate negative )

-0.39
( neutral )

-0.17
( neutral )

0.23
( neutral )

-0.26
( neutral )

Orphazyme A/S Finanse

Annual	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2019
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-16.87

FY	2018
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-11.50

Financial Reports:

No articles found.

Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.